- Stocks
- Healthcare
- NASDAQ: AMGN

Price (delayed)

$283.51

Market cap

$151.94B

P/E Ratio

22.57

Dividend/share

$8.64

EPS

$12.56

Enterprise value

$205.61B

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world's largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980.

The revenue has grown by 7% year-on-year and by 5% since the previous quarter

Amgen's equity has soared by 70% YoY but it has decreased by 19% from the previous quarter

AMGN's quick ratio has dropped by 59% since the previous quarter but it is up by 4.2% year-on-year

The debt has surged by 66% year-on-year and by 7% since the previous quarter

The P/E is 23% above the last 4 quarters average of 18.3 and 18% above the 5-year quarterly average of 19.1

What are the main financial stats of AMGN

Market
Valuations
Earnings

Shares outstanding

535.92M

Market cap

$151.94B

Enterprise value

$205.61B

Price to earnings (P/E)

22.57

Price to book (P/B)

24.35

Price to sales (P/S)

5.38

EV/EBIT

19.16

EV/EBITDA

13.89

EV/Sales

7.29

Revenue

$28.19B

EBIT

$10.73B

EBITDA

$14.8B

Free cash flow

$7.36B

Per share
Balance sheet
Liquidity

EPS

$12.56

Free cash flow per share

$13.76

Book value per share

$11.64

Revenue per share

$52.69

TBVPS

$85.76

Total assets

$97.15B

Total liabilities

$90.92B

Debt

$64.61B

Equity

$6.23B

Working capital

$11.94B

Debt to equity

10.37

Current ratio

1.65

Quick ratio

0.99

Net debt/EBITDA

3.63

Margins
Efficiency
Dividend

EBITDA margin

52.5%

Gross margin

70%

Net margin

23.8%

Operating margin

28%

Return on assets

7.3%

Return on equity

103.3%

Return on invested capital

14.5%

Return on capital employed

13.6%

Return on sales

38.1%

Dividend yield

3.05%

DPS

$8.64

Payout ratio

68.8%

How has the Amgen stock price performed over time

Intraday

-0.07%

1 week

-2.4%

1 month

-7.89%

1 year

17.87%

YTD

-1.57%

QTD

-1.57%

How have Amgen's revenue and profit performed over time

Revenue

$28.19B

Gross profit

$19.74B

Operating income

$7.9B

Net income

$6.72B

Gross margin

70%

Net margin

23.8%

The company's operating margin fell by 23% YoY and by 15% QoQ

AMGN's operating income is down by 17% year-on-year and by 11% since the previous quarter

The net margin has declined by 16% since the previous quarter and by 4.4% year-on-year

The net income has contracted by 11% from the previous quarter but it has grown by 2.5% YoY

What is Amgen's growth rate over time

What is Amgen stock price valuation

P/E

22.57

P/B

24.35

P/S

5.38

EV/EBIT

19.16

EV/EBITDA

13.89

EV/Sales

7.29

The P/E is 23% above the last 4 quarters average of 18.3 and 18% above the 5-year quarterly average of 19.1

AMGN's EPS is down by 11% since the previous quarter but it is up by 3.1% year-on-year

Amgen's equity has soared by 70% YoY but it has decreased by 19% from the previous quarter

The stock's price to book (P/B) is 14% more than its last 4 quarters average of 21.3 but 7% less than its 5-year quarterly average of 26.2

The revenue has grown by 7% year-on-year and by 5% since the previous quarter

The P/S is 5% more than the last 4 quarters average of 5.1 and 3.5% more than the 5-year quarterly average of 5.2

How efficient is Amgen business performance

The ROE has plunged by 58% YoY and by 20% from the previous quarter

AMGN's return on assets is down by 31% year-on-year and by 19% since the previous quarter

The ROIC has contracted by 19% YoY and by 15% from the previous quarter

AMGN's return on sales is up by 15% year-on-year but it is down by 9% since the previous quarter

What is AMGN's dividend history

DPS

$8.64

Dividend yield

3.05%

Payout ratio

68.8%

Recent dividends

How did Amgen financials performed over time

Amgen's total assets is 7% more than its total liabilities

AMGN's quick ratio has dropped by 59% since the previous quarter but it is up by 4.2% year-on-year

Amgen's total assets has increased by 49% YoY and by 7% from the previous quarter

Amgen's equity has soared by 70% YoY but it has decreased by 19% from the previous quarter

The debt has surged by 66% year-on-year and by 7% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.